189 related articles for article (PubMed ID: 32514626)
1. Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma.
Stemler J; Koehler P; Maurer C; Müller C; Cornely OA
Ann Hematol; 2020 Jul; 99(7):1429-1440. PubMed ID: 32514626
[TBL] [Abstract][Full Text] [Related]
2. New Targeted Drugs for Acute Myeloid Leukemia and Antifungals: Pharmacokinetic Challenges and Opportunities.
Salvatorelli E; Minotti G; Menna P
Chemotherapy; 2023; 68(3):170-182. PubMed ID: 37004510
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML).
Sechaud R; Sinclair K; Grosch K; Ouatas T; Pathak D
Cancer Chemother Pharmacol; 2022 Jul; 90(1):19-27. PubMed ID: 35751657
[TBL] [Abstract][Full Text] [Related]
4. Quantification of midostaurin in plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry: Application to a cohort of patients with acute myeloid leukemia.
Wiesen MHJ; Stemler J; Fietz C; Joisten C; Cornely OA; Verougstraete N; Streichert T; Müller C
Eur J Haematol; 2024 Jun; 112(6):879-888. PubMed ID: 38297484
[TBL] [Abstract][Full Text] [Related]
5. Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia.
White O; Kennedy E; Huckabee JB; Rogers E; LeBlanc TW; Dillon M; Li Z; Hanna D
J Oncol Pharm Pract; 2024 Apr; 30(3):527-534. PubMed ID: 37186784
[TBL] [Abstract][Full Text] [Related]
6. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Stemler J; Mellinghoff SC; Khodamoradi Y; Sprute R; Classen AY; Zapke SE; Hoenigl M; Krause R; Schmidt-Hieber M; Heinz WJ; Klein M; Koehler P; Liss B; Koldehoff M; Buhl C; Penack O; Maschmeyer G; Schalk E; Lass-Flörl C; Karthaus M; Ruhnke M; Cornely OA; Teschner D
J Antimicrob Chemother; 2023 Aug; 78(8):1813-1826. PubMed ID: 37311136
[TBL] [Abstract][Full Text] [Related]
7. Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study.
Menna P; Marchesi F; Cattaneo C; Candoni A; Delia M; Nadali G; Vatteroni A; Pasciolla C; Perrone S; Verga L; Armiento D; Del Principe MI; Fracchiolla NS; Salvatorelli E; Lupisella S; Terrenato I; Busca A; Minotti G; Pagano L
Clin Transl Sci; 2023 Oct; 16(10):1876-1885. PubMed ID: 37515369
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia.
Tu S; Zhang K; Wang N; Chu J; Yang L; Xie Z
Sci Rep; 2023 Nov; 13(1):18789. PubMed ID: 37914820
[TBL] [Abstract][Full Text] [Related]
9. Should patients with acute myeloid leukemia treated with venetoclax-based regimens receive antifungal prophylaxis?
Guarana M; Nucci M
Leuk Res; 2023 Aug; 131():107341. PubMed ID: 37327641
[TBL] [Abstract][Full Text] [Related]
10. Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
Dinh A; Savoy JM; Kontoyiannis DP; Takahashi K; Issa GC; Kantarjian HM; DiNardo CD; Rausch CR
Cancer; 2024 Jun; 130(11):1964-1971. PubMed ID: 38340331
[TBL] [Abstract][Full Text] [Related]
11. Clinically relevant bidirectional drug-drug interaction between midostaurin and voriconazole.
Haefliger D; Marzolini C; Lamoth F; Pabst T; Buclin T; Livio F
Br J Clin Pharmacol; 2023 Jul; 89(7):2304-2308. PubMed ID: 37050863
[TBL] [Abstract][Full Text] [Related]
12. Invasive fungal infection following venetoclax and posaconazole co-administration.
Reynolds G; Urbancic KF; Fong CY; Trubiano JA
Br J Haematol; 2023 Nov; 203(4):593-598. PubMed ID: 37731068
[TBL] [Abstract][Full Text] [Related]
13. The impact of antifungal prophylaxis in patients diagnosed with acute leukemias undergoing induction chemotherapy: a systematic review and meta-analysis.
Soldi LR; Coelho YNB; Paranhos LR; Silva MJB
Clin Exp Med; 2023 Nov; 23(7):3231-3249. PubMed ID: 37058186
[TBL] [Abstract][Full Text] [Related]
14. Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions.
Lionakis MS; Lewis RE; Kontoyiannis DP
Clin Infect Dis; 2018 Oct; 67(10):1621-1630. PubMed ID: 29860307
[TBL] [Abstract][Full Text] [Related]
15. Midostaurin as the Most Likely Cause of Bilateral Adrenal Masses in a Patient with Acute Myeloid Leukemia.
Schutte T; Stege CAM; Smits MM; Franssen LE; Donker ML; de Leeuw DC
Clin Drug Investig; 2022 Sep; 42(9):791-797. PubMed ID: 35948754
[No Abstract] [Full Text] [Related]
16. Antifungal Drug-Drug Interactions with Commonly Used Pharmaceutics in European Pediatric Patients with Acute Lymphoblastic Leukemia.
Sienkiewicz-Oleszkiewicz B; Salamonowicz-Bodzioch M; Słonka J; Kałwak K
J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510753
[TBL] [Abstract][Full Text] [Related]
17. Cushing syndrome and tertiary adrenal insufficiency from prolonged concomitant use of budesonide and posaconazole.
Grigg A
Intern Med J; 2024 Mar; 54(3):488-490. PubMed ID: 38404123
[TBL] [Abstract][Full Text] [Related]
18. Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges?: Summary of the EHA Guideline on Antifungal Prophylaxis in Adult Patients With Acute Myeloid Leukemia Treated With Novel-targeted Therapies.
Stemler J; Cornely OA
Hemasphere; 2022 Jul; 6(7):e742. PubMed ID: 35747590
[No Abstract] [Full Text] [Related]
19. Correction Notice: Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges? Summary of the EHA Guideline on Antifungal Prophylaxis in Adult Patients With Acute Myeloid Leukemia Treated With Novel-targeted Therapies.
Hemasphere; 2022 Jul; 6(7):e756. PubMed ID: 35813103
[TBL] [Abstract][Full Text] [Related]
20. Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use.
Abdul-Hamil NA; Wong GC; Nagarajan C; Martinelli G; Cherchione C
Minerva Med; 2020 Oct; 111(5):443-454. PubMed ID: 32955824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
